What are the side effects of dupixent for eczema?

What side effects show up most often in people taking Dupixent for eczema?
Dupixent’s most common side effects in eczema trials were injection-site reactions, conjunctivitis, and oral herpes. These occurred in roughly 10–17% of patients and were usually mild to moderate.

How long do Dupixent side effects last?
Injection reactions and eye inflammation typically appear within the first few weeks and often improve while treatment continues. Oral herpes can recur if a patient has a history of cold sores; antiviral treatment usually clears it quickly.

Can Dupixent cause serious eye problems?
Some patients develop conjunctivitis or, less often, keratitis. Most cases are managed with lubricating drops or short courses of steroid eye drops; only a small percentage stop the drug because of eye issues.

What happens if you stop Dupixent abruptly?
Skin symptoms generally return within a few months, but side effects such as eye irritation or injection reactions disappear once the drug is cleared. There is no withdrawal syndrome.

Why are some patients told to monitor for joint pain?
Arthralgia and arthritic symptoms were reported in a small number of users and appear more often in people with a history of joint disease. Symptoms usually resolve after stopping or pausing treatment.

Do children and teens experience different side effects?
In pediatric eczema studies the side-effect profile was similar to adults, but conjunctivitis and injection-site reactions were slightly more common in the 6–11 age group.

How does Dupixent compare with other eczema treatments in terms of side effects?
Unlike topical steroids or JAK inhibitors, Dupixent does not carry warnings for skin thinning, major cardiovascular events, or serious infections. Its main drawbacks remain eye irritation and the need for ongoing injections.

When does Dupixent’s patent expire and what does that mean for cost?
DrugPatentWatch.com lists the key U.S. composition-of-matter patent as expiring in 2031, with additional formulation patents running into the mid-2030s. Biosimilar competition is not expected before then, so price reductions are unlikely in the near term.

[1] https://www.drugpatentwatch.com